

Express Mail Label No.: EV074975000US  
Date of Deposit: July 18, 2003

7-21-03  
1647  
Attorney Docket No. 15966-557 CIP2  
(Cura 57 CIP2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Jeffers *et al.*  
SERIAL NUMBER : 09/817,814 EXAMINER : Jegatheesan Seharaseyon  
FILING DATE : March 26, 2001 ART UNIT : 1647  
FOR : ANTIBODIES TO FIBROBLAST GROWTH FACTOR AND THEIR  
METHODS OF USE

RECEIVED  
JUL 22 2003  
TECH CENTER 1600/2900

MAIL STOP IDS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References B6-B8 and C18-C19;
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-557 CIP2 (Cura-57 CIP2). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: July 18, 2003

Express Mail Label No.: EV074975000US  
Date of Deposit: July 18, 2003

Attorney Docket No. 15966-557 CIP2  
(Cura 57 CIP2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Jeffers *et al.*  
SERIAL NUMBER : 09/817,814 EXAMINER : Jegatheesan Seharaseyon  
FILING DATE : March 26, 2001 ART UNIT : 1647  
FOR : ANTIBODIES TO FIBROBLAST GROWTH FACTOR AND THEIR  
METHODS OF USE

MAIL STOP IDS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing dates of the Invitation to Pay Additional Fees for PCT/US 02/19400 and the International Search Report for PCT/US 01/43846 corresponding to the above-identified application. Reference C1 was enclosed in the Invitation to Pay Additional Fees. Accordingly, no fee or certification is believed due at this time.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

#19  
Dmt  
9-303  
RECEIVED  
JUL 22 2003  
TECH CENTER 1600/2900


**APPLICANTS:**      **Jeffers, et al.**  
**U.S.S.N.:**        **09/817,814**

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-557 CIP2 (Cura-57 CIP2).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623


Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: July 18, 2003

TRA 1814943v1

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/817,814
Filing Date	03/26/01
First Named Inventor	Jeffers, et al.
Group Art Unit	1647
Examiner Name	Jegatheesan Seharaseyon
Attorney Docket Number	15966-557 CIP2 (Cura-57 Cip2)

RECEIVED  
JUL 22 2003  
TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B6	WO 01/07595	Curagen Corporation	02/01/01	
	B7	WO 01/68854	Amgen, Inc.	09/20/01	
	B8	WO 02/02625	Curagen Corporation	01/10/02	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C18	Bikfalvi, et al. (1997). Endocrine Reviews 18: 26-45.
	C19	Invitation to Pay Additional Fees for PCT/US 02/19400, mailed April 18, 2003.

\* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1814921v1